Apellis Pharmaceuticals, Inc. (APLS) is a publicly traded company in the Unknown sector. Across all available filings, 32 corporate insiders have executed 890 transactions totaling $248.1M, demonstrating a bearish sentiment with -$74.0M in net insider flow. The most recent transaction on Feb 3, 2026 involved a transaction of 8,840 shares valued at $0.
No significant insider buying has been recorded for APLS in the recent period.
No significant insider selling has been recorded for APLS in the recent period.
Based on recent SEC filings, insider sentiment for APLS is bearish with an Insider Alignment Score of 35/100 and a net flow of -$74.0M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Apellis Pharmaceuticals, Inc. (APLS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 32 insiders are actively trading APLS stock, having executed 890 transactions in the past 90 days. The most active insider is Cedric Francois (Executive), who has made 124 transactions totaling $55.9M.
Get notified when executives and directors at APLS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Francois Cedric | Executive | Option Exercise | 8,840 | $N/A | $0 | |
| Feb 3, 2026 | Francois Cedric | Executive | Option Exercise | 8,840 | $3.76 | $33.2K | |
| Jan 28, 2026 | Nicholson Nur | Chief Technical Officer | Award | 45,220 | $N/A | $0 | |
| Jan 28, 2026 | Meltzer Leslie | Chief Research and Development | Award | 45,220 | $N/A | $0 | |
| Jan 28, 2026 | Deschatelets Pascal | Chief Scientific Officer | Award | 25,840 | $N/A | $0 | |
| Jan 28, 2026 | Jeffrey Delong Mark | Chief Business & Strat Officer | Award | 36,606 | $N/A | $0 | |
| Jan 28, 2026 | George Chopas James | VP/Chief Accounting Officer | Award | 16,150 | $N/A | $0 | |
| Jan 28, 2026 | Boucher Kelley | Chief People Officer | Award | 30,146 | $N/A | $0 | |
| Jan 22, 2026 | O. Watson David | General Counsel | Sale | 7,832 | $21.77 | $170.5K | |
| Jan 22, 2026 | Eugene Sullivan Timothy | Chief Financial Officer | Sale | 10,287 | $21.77 | $223.9K | C-Suite |
| Jan 22, 2026 | Nicholson Nur | Chief Technical Officer | Sale | 7,725 | $21.77 | $168.1K | |
| Jan 22, 2026 | Francois Cedric | Executive | Sale | 27,192 | $21.77 | $591.8K | Large |
| Jan 22, 2026 | Deschatelets Pascal | Chief Scientific Officer | Sale | 5,928 | $21.77 | $129.0K | |
| Jan 20, 2026 | Eugene Sullivan Timothy | Chief Financial Officer | Sale | 2,892 | $19.79 | $57.2K | C-Suite |
| Jan 20, 2026 | Nicholson Nur | Chief Technical Officer | Sale | 2,203 | $19.79 | $43.6K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 395 | $161.1M | 59.3% |
Purchase(P) | 17 | $87.1M | 32.0% |
Exercise(M) | 223 | $19.6M | 7.2% |
Payment(F) | 78 | $4.0M | 1.5% |
Award(A) | 114 | $0 | 0.0% |
Other(J) | 23 | $0 | 0.0% |
Gift(G) | 33 | $0 | 0.0% |
Conversion(C) | 7 | $0 | 0.0% |
Insider selling pressure at Apellis Pharmaceuticals, Inc. has increased, with 32 insiders executing 890 transactions across all time. Total sales of $161.1M significantly outpace purchases of $87.1M, resulting in a net outflow of $74.0M. This selling activity appears largely discretionary, which may warrant closer attention from investors.